期刊文献+

无血清培养脐带间充质干细胞的研究 被引量:1

Serum-free Culture of Umbilical Cord Mesenchymal Stem Cells
下载PDF
导出
摘要 本研究观察无血清培养液培养的人脐带间充质干细胞(UC-MSC),并比较与含10%胎牛血清培养液培养的人脐带间充质干细胞的异同。采集正常足月剖宫产胎儿脐带,用MesenCult-XF无血清培养液或含10%胎牛血清培养液培养。观察不同培养液培养的间充质干细胞细胞的形态、免疫表型、细胞周期、增殖分化潜能及对混合淋巴细胞反应的抑制作用。结果表明,采用无血清MesenCult-XF培养液培养的MSC平均传代倍增6.57±0.7倍,含血清培养液培养的MSC平均传代倍增4,59±0.45倍(P<0.05);两种培养液培养的MSC均表达CD44、CD90、CD73、CD105抗原,不表达CD31、CD45、HLA-DR及CD34等抗原,表达程度无明显统计学差异;无血清培养液培养的MSC(65±5.2)%均为G o/G1期细胞,含血清培养液培养的MSC(62±3.1)%为G o/G1期细胞(P>0.05);两种培养液培养的人脐带MSC均可向成脂细胞、成骨细胞分化;无血清培养液培养的脐带MSC按1 000、5 000、10 000、20 000个细胞/孔接种密度与反应细胞和刺激细胞共培养的每分钟闪烁值(CPM)分别为(6.43±0.47)×104、(4.30±0.38)×104、(1.97±0.13)×104和(0.24±0.03)×104,含血清培养液培养的MSC与不同密度的混合淋巴细胞共培养的CPM值分别为(7.85±0.07)×104、(5.64±0.12)×104、(3.09±0.18)×104和(1.73±0.05)×104。结论:无血清培养液培养的细胞均为MSC,有传代增殖潜能,传代可达临床治疗MSC细胞量,并可避免异种蛋白致敏。 This study was purposed to observe the culture of umbilical cord mesenchymal stem cells (UC-MSC) with serum-free medium, and compared it with the medium containing 10% fetal bovine serum(FBS). The normal umbilical cords were acquired during cesarean section, and then were cultured with MesenCult-XF serum-free medium or medium containing 10% fetal bovine serum (FBS). The monphology, immunophenotype, cell cycle, proliferation and differentiation potential of mesenchymal stem cells and the inhibition of mixed lymphocyte reaction were observed through different medium culture method. The results showed that the MSC cultured with serum-free MesenCult-XF medium could transfer and multiply for average of 6.57 ± 0.7 times, and the serum medium-cultured MSC could transfer and multiply for average of 4.59 ± 0.45 times ( P 〈 0. 05 ). Two kinds of medium cultured MSC all expressed CD44, CD90, CD73, CD105 antigen, but did not expressed CD31, CIM5, HLA-DR and CD34 antigen, and their expression levels were not significantly different. The serum-free medium-cultured MSC (65 ± 5.2% ) were all at G0/G1 phase, and the serum-contained medium-cultured MSC (62 ±3.1% ) were at G0/G1 phase(P 〉0. 05) ; the 2 kinds of media- cultured MSC all could differentiate into fat and ossification; when serum-free medium cultured umbilical cord MSC were innoculated at the the density of 103 , 5 × 103 , 104, and 2 × 104 cells/well, then co-cultured with the reactant and stimulating cells, the CPM were (6. 43 ± 0. 47 ) × 104, (4. 30 ± 0. 38 ) × 104, ( 1.97 ± 0. 13 ) × 104 and ( 0. 24 ± 0. 03 ) × 104, respectively, and the serum-containing medium-cultured MSC were incubated with different density of mixed lymphocyte, displaying CPM that were (7.85 ±0.07) × 104 , (5.64 ±0.12) × 104, (3.09 ±0.18) × 104 and ( 1.73 ± 0. 05)× 104. It is concluded that the serum-free medium has been confirmed to culture MSC, which have potential of transfer and differentiation with count for clinical application, and can avoid foreign protein sensitization.
出处 《中国实验血液学杂志》 CAS CSCD 北大核心 2013年第5期1256-1260,共5页 Journal of Experimental Hematology
基金 江苏省卫生厅面上项目(H201212) 苏州市科技发展计划项目(SS0718) 江苏省临床医学中心血液病学开放课题编号(KF200943)
关键词 脐带间充质干细胞 无血清培养液 MesenCult-XF无血清培养液 细胞治疗 umbilical cord mesenchymal stem cell serum free medium MesenCult-XF serum-free medium celltherapy
  • 相关文献

参考文献14

  • 1Frideenstein A,Chailankhyan R,Gerasimov U.Bone marrow osteogenic stem cells:in vitro cultivation and transplantation in diffusion chambers.Cell Tissue kinet,1987,20:263-272.
  • 2Satija NK,Singh VK,Venna YK,et al.Mesenchymal stem cellbased therapy:a new paradigm in regenerative medicine.J Cell Mol Med,2009; 13(11-12):4385-4402.
  • 3Koc ON,Gerson SL,Cooper BW,et al.Rapid hematopoietic recovery after coinfusion of autologous blood stem cells and culture expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high dose chemothyrapy.J Clin Oncol,2000; 18(2):3072316.
  • 4Le Blanc K,Tammik L,Sundberg B,et al.Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic re2 sponces independently of the major histocompa-tibility complex.Scand J Immunol,2003 ; 57(1):11220.
  • 5陈广华,杨婷,田竤,乔曼,刘慧文,傅琤琤,苗瞄,金正明,唐晓文,韩悦,何广胜,张旭辉,马骁,陈峰,胡晓慧,薛胜利,王荧,仇慧英,孙爱宁,陈志哲,吴德沛.脐带间充质干细胞治疗糖皮质激素耐药的严重型急性移植物抗宿主病19例分析[J].中华血液学杂志,2012,33(4):303-306. 被引量:12
  • 6Le Blanc K,Frassoni F,Ball L,et al.Mesenchymal stem cells for treatment of steroid-resistant,severe,acute graft-versus-host disease:a phase Ⅱ study.Lancet 2008 ; 371 (9624):1579-1586.
  • 7Spees JL,Gregory CA,Singh H,et al.Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy.Mol Ther 2004; 9 (5):747-756.
  • 8Sundin M,Ringdén O,Sundberg B,et al.No alloantibodies against mesenchymal stromal cells,but presence of anti-fetal calf serum antibodies,after transplantation in allogeneic hematopoietic stem cell recipients.Haematologica 2007 ; 92(9):1208-1215.
  • 9Kocaoemer A,Kern S,Kluter H,et al.Human AB serum and thrombin-activated platelet-rich plasma are suitable alternatives to fetal calf serum for the expansion of mesenchymal stem cells from adipose tissue.Stem Cells 2007 ;25 (5):1270-1278.
  • 10Doucet C,Ernou I,Zhang Y,et al.Platelet lysates promote mesenchymal stem cell expansion:A safety substitute for animal serum in cell-based therapy applications.J Cell Physiol 2005 ; 205(2):228-236.

二级参考文献13

  • 1Deeg HJ. How I treat refractory acute GVHD[J].Blood,2007.4119-4126.
  • 2MacMillan ML,DeFor TE,Weisdorf DJ. The best endpoint for acute GVHD treatment trials[J].Blood,2010.5412-5417.
  • 3Socie G,Blazar BR. Acute graft-versus-host disease;from the bench to the bedside[J].Blood,2009.4327-4336.
  • 4English K,French A,Wood KJ. Mesenchymal stromal cells:facilitators of successful transplantation[J].Cell Stem Cell,2010.431-442.
  • 5Le Blanc K,Rasmusson I,Sundberg B. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells[J].The Lancet,2004.1439-1441.
  • 6Le Blanc K,Frassoni F,Ball L. Mesenchymal stem cells for treatment of steroid-resistant,severe,acute graft-versus-host disease;a phase II study[J].The Lancet,2008.1579-1586.
  • 7Weiss ML,Medicetty S,Bledsoe AR. Human umbilical cord matrix stem cells:preliminary characterization and effect of transplantation in a rodent model of Parkinson' s disease[J].Stem Cells,2006.781-792.
  • 8Weiss ML,Anderson C,Medicetty S. Immune properties of human umbilical cord Wharton's jelly-derived cells[J].Stem Cells,2008.2865-2874.
  • 9Dominici M,Le Blanc K,Mueller I. Minimal criteria for defining multipotent mesenchymal stromal cells.The International Society for Cellular Therapy position statement[J].Cytotherapy,2006.315-317.doi:10.1080/14653240600855905.
  • 10Baron F,Lechanteur C,Willems E. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease(GVHD)without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning[J].Biology of Blood and Marrow Transplantation,2010.838-847.

共引文献11

同被引文献3

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部